Aurora Cannabis Inc. is a leading company in the cannabis industry, primarily focused on the production and distribution of medical and recreational cannabis products
With a commitment to sustainability and innovation, the company cultivates a diverse range of cannabis strains and products, including dried flower, oils, and edibles, aimed at meeting the demands of consumers and patients alike. Aurora operates through a network of facilities and has established a strong presence in multiple international markets, working to advance the understanding and benefits of cannabis through research and development. The company is dedicated to promoting responsible usage and prioritizes quality and compliance within its operations.
The U.S. Customs and Border Protection (CBP) and Department of Homeland Security (DHS) are asking a federal judge to dismiss a case brought by New Mexico-licensed cannabis businesses. The businesses allege that the agencies unlawfully seized state-regulated cannabis products and arrested staff members at checkpoints within the state.
Researchers from the Center for Addiction and Mental Health (CAMH) are exploring the ethical implications of marijuana research that’s largely funded by actors with industry interests. Prior to the recent wave of state-level legalization, studying the potential risks and benefits of marijuana was practically impossible, making the recent rush of cannabis-related studies even more important for the fledgling cannabis market.
Democrats in Pennsylvania are making another attempt to legalize cannabis through new legislation spearheaded by state Representatives Dan Frankel from Allegheny County and Rick Krajewski from Philadelphia. They are currently seeking co-sponsors for their proposal, marking the latest effort in a series of attempts over recent years to address cannabis legalization in the state.
Last week, a judge in Ramsey County stopped a lottery that would’ve awarded marijuana licenses in Minnesota. This is a huge setback for regulators in the state, who are prepping for legal sales come 2025.
Aurora Cannabis Inc. (NASDAQACB) (TSX: ACB), announced on Tuesday developments in cannabis science from Aurora's research and genetics facility, Aurora Coast."As a company committed to leading the way in terms of cannabis innovation, we are dedicated to putting patients first by harnessing the innovative solutions developed by our top researchers at Aurora Coast, our unique global research facility," Lana Culley, vice president of science and innovation at Aurora. "We strive to continuously raise the bar on product superiority and overall user experience so that we can deliver on our mission of providing patients with access to the very best medical cannabis."
Australian legislators are preparing to vote on legislation that could pave the way for adult-use cannabis legalization across the nation. Senator David Shoebridge of the Greens Party, who has spearheaded the effort, announced on social media that the proposed bill is scheduled for a vote in Parliament on November 27.
Cannabis company Canopy Growth Corporation (TSX: WEED) (NASDAQCGC) is launching the award-winning California-grown Claybourne brand in Canada, via an exclusive licensing agreement. Canadian medical cannabis company Aurora Cannabis Inc. NASDAQ: ACBNASDAQACB)
David Heldreth, CEO and founder of Panacea Plant Sciences, has filed a federal court lawsuit, claiming the DEA breached several legal protocols in preparing for a hearing on the Biden administration’s proposal to reclassify marijuana. The suit urges the court to issue an injunction halting the DEA’s scheduled hearing until these legal concerns are addressed.
Aurora's leadership in global medical cannabis and ability to capitalize on opportunities within rapidly growing markets such as Australia, Germany, Poland, and the UK was clearly demonstrated in Q2 and is expected to continue in Q3.
Advocates in New Jersey are currently debating whether the state’s Marijuana Regulatory Commission should raise the fee directing revenue from recreational cannabis sales to fund social equity initiatives and support communities affected by past drug policies. The commission is set to meet soon to determine the fee rate that will apply starting January 1. Presently, the fee is set at $1.24 per ounce .
